PyroCells
Cancer (solid tumors, adjuvant setting)
Pre-clinicalActive
Key Facts
About Pyrojas
Pyrojas is a private, pre-clinical stage biotech founded in 2016 and based in San Diego, CA, focused on next-generation cancer vaccines. Its core technology, PyroCells, is an autologous whole tumor cell vaccine designed to overcome tumor heterogeneity by presenting the full antigenic landscape to the immune system, aiming to prevent relapse. With backing from the National Cancer Institute (NCI), Bristol Myers Squibb, and venture capital, and guided by a world-class scientific advisory board, the company is preparing to translate its promising pre-clinical results into human trials. Pyrojas also offers a licensing opportunity for its PyroTIMER technology, a T cell function booster.
View full company profile